Journal article icon

Journal article

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Abstract:

OBJECTIVE: Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular degeneration (AMD) compared monthly and every-2-month dosing of intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizumab. DESIGN: Double-masked, multicenter, parallel-group, active-controlled, randomized trials. PARTICIPANTS: Patients (n = 2419)...

Expand abstract

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Korobelnik, JF More by this author
Kaiser, PK More by this author
Expand authors...
Journal:
Ophthalmology
Volume:
119
Issue:
12
Pages:
2537-2548
Publication date:
2012-12-05
DOI:
EISSN:
1549-4713
ISSN:
0161-6420
URN:
uuid:e05ddbe8-3e4e-47f8-88fd-01a8a90bfef3
Source identifiers:
368347
Local pid:
pubs:368347

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP